Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BT-KTM-I vs Ketanest® S for General Anesthesia
NCT06092684Phase 3Completed
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esketamine (2 arms), sponsored by Chengdu Brilliant Pharmaceutical Co., Ltd. Primary endpoint: The awakening time from anesthesia. Started Sep 2023; status: completed.
02
Drugs
esketamine
Beyond the preview
Go deeper on NCT06092684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092684.